Longeveron (LGVN) Investor presentation summary

Strategic repositioning and leadership

• New CEO Steve Willard appointed in February 2026, bringing experience in billion-dollar valuations and major licensing deals.

• Shift to a capital-light model, prioritizing HLHS Phase 2b data readout in August 2026 to extend cash runway.

• Focus on securing high-value global licensing opportunities for laromestrocel across multiple indications.

• Completed up to $30M financing in March 2026, led by fundamental investors.

• Strong scientific leadership and robust IP portfolio with 50+ issued and 60+ pending patents.

Clinical pipeline and lead programs

• Laromestrocel (Lomecel-B) is a first-in-class allogeneic cell therapy with five FDA expedited designations.

• Lead indication HLHS: Phase 2b (ELPIS II) fully enrolled, top-line data expected August 2026; Phase 1 showed 100% transplant-free survival at 5 years.

• PDCM: IND approved for a single Phase 2 registration study; $1B+ global market opportunity.

• Alzheimer's: Phase 2a (CLEAR MIND) showed positive brain volume preservation; only cellular therapy with FDA RMAT designation for AD.

• Aging-related Frailty: Phase 2b completed, positive efficacy signal published in Cell Stem Cell.

Addressing unmet medical needs

• HLHS is a terminal orphan pediatric heart defect with no approved medicinal therapies and high mortality.

• PDCM affects at least 100,000 children globally, with high mortality and limited treatment options.

• Alzheimer's disease impacts over 32 million globally, with rising prevalence and costs.

• Aging-related frailty affects over 1.4 billion people worldwide by 2030, with no approved treatments.